CONFIDENTIALEmployment Agreement • December 23rd, 1999 • Ben Abraham Technologies Inc • Illinois
Exhibit 10.20 BIOSANTE PHARMACEUTICALS, INC. SUBSCRIPTION AGREEMENT BioSante Pharmaceuticals, Inc. 175 Olde Half Day Road, Suite 247 Lincolnshire, IL 60069 Attn: Mr. Stephen M. Simes Ladies and Gentlemen: 1. SUBSCRIPTION. The undersigned is hereby...Subscription Agreement • June 29th, 2001 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Illinois
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 17th, 2012 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of August 16, 2012, between BioSante Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
FIRST AMENDMENT TO LEASELease • March 26th, 2004 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances)
EXHIBIT 2 FORM OF INCENTIVE STOCK OPTION AGREEMENT THIS AGREEMENT is entered into and effective as of this ____ day of _____________, ____ (the "Date of Grant"), by and between BioSante Pharmaceuticals, Inc., a Delaware corporation (the "Company"),...Incentive Stock Option Agreement • August 22nd, 2001 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Illinois
R E C I T A L S:Shareholder Agreement • December 23rd, 1999 • Ben Abraham Technologies Inc • Illinois
FORM C ESCROW AGREEMENTEscrow Agreement • December 23rd, 1999 • Ben Abraham Technologies Inc • Ontario
SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this "AGREEMENT"), dated as of May 6, 1999, by and among BEN-ABRAHAM TECHNOLOGIES INC., a Wyoming corporation (the "COMPANY"), and each other person executing this Agreement as set...Securities Purchase Agreement • December 23rd, 1999 • Ben Abraham Technologies Inc • Illinois
RECITALSSublease Agreement • September 14th, 2001 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances)
CONFIDENTIALEmployment Agreement • February 24th, 2000 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Illinois
OFFICE LEASE BETWEENOffice Lease • March 26th, 2004 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances)
LASALLE BANK NATIONAL ASSOCIATION, AS SUCCESSOR TRUSTEE TO AMERICAN NATIONAL BANK AND TRUST COMPANY OF CHICAGO, as Trustee under Trust Agreement dated January 1, 1991 and known as Trust No. 113370-03
Exhibit 4.2 FORM OF WARRANT Warrant to Purchase Up To ______________ Shares Of Common Stock of BioSante Pharmaceuticals, Inc. THIS CERTIFIES that, for value received, ________________ ("Investor") or any transferee of Investor (Investor or such...Warrant Agreement • June 29th, 2001 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Illinois
THIS WARRANT AND THE SUBORDINATE VOTING SHARES TO BE SOLD UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED...Warrant Agreement • December 23rd, 1999 • Ben Abraham Technologies Inc • Illinois
RECITALSEmployment Agreement • March 30th, 2001 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Illinois
WARRANTSecurities Agreement • May 14th, 2004 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances)
HIGHLANDS PARK ASSOCIATES C/O BAKER-DENNARD CO. PLAZA SQUARE NORTH SUITE 450 4360 CHAMBLEE-DUNWOODY ROAD ATLANTA, GEORGIA 30341 HIGHLANDS PARK ASSOCIATES LEASE AGREEMENTLease Agreement • December 23rd, 1999 • Ben Abraham Technologies Inc • Georgia
Common Stock Purchase Warrant BIOSANTE PHARMACEUTICALS, INC.Common Stock Purchase Warrant • August 17th, 2012 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances)
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from BioSante Pharmaceuticals, Inc., a Delaware corporation (the “Company”), up to shares (the “Warrant Shares”) of Common Stock.
CONFIDENTIALEmployment Agreement • March 30th, 2001 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Illinois
BETWEENLicense Agreement • July 11th, 2000 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Illinois
FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT FOR SELECTED APPLICATIONS OF COATED NANOCRYSTALLINE PARTICLES BETWEENExclusive License Agreement • March 24th, 2000 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances)
VOTING AGREEMENT ----------------Voting Agreement • December 23rd, 1999 • Ben Abraham Technologies Inc • Illinois
RECITALSRegistration Rights Agreement • December 23rd, 1999 • Ben Abraham Technologies Inc • Illinois
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 14th, 2009 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of August 13, 2009, between BioSante Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
EXHIBIT 10.31 NON-STATUTORY STOCK OPTION AGREEMENT THIS AGREEMENT is entered into and effective as of this ______ day of ________, ____ (the "Date of Grant"), by and between BioSante Pharmaceuticals, Inc., a Delaware corporation (the "Company"), and...Non-Statutory Stock Option Agreement • March 26th, 2004 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Illinois
WITNESSETH:Subscription Agreement • May 12th, 2004 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
CONFIDENTIAL Stephen M. Simes President & Chief Executive Officer BioSante Pharmaceuticals, Inc.Placement Agent Agreement • August 17th, 2012 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
ARTICLE 1 INTERPRETATIONArrangement Agreement • December 23rd, 1999 • Ben Abraham Technologies Inc • Ontario
FORM OF COMMON STOCK PURCHASE WARRANT To Purchase «Shares» Shares of Common Stock of BIOSANTE PHARMACEUTICALS, INC.Warrant Agreement • August 6th, 2003 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
THIS IS TO CERTIFY THAT «Name», or registered assigns (the “Holder”), is entitled, during the Exercise Period (as hereinafter defined), to purchase from BioSante Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the Warrant Stock (as hereinafter defined and subject to adjustment as provided herein), in whole or in part, at a purchase price of $2.15 per share, all on and subject to the terms and conditions hereinafter set forth.
ANI PHARMACEUTICALS, INC. AND THE BANK OF NEW YORK MELLON, as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of December 10, 2014 3.00% Convertible Senior Notes due 2019First Supplemental Indenture • December 10th, 2014 • Ani Pharmaceuticals Inc • Pharmaceutical preparations
FIRST SUPPLEMENTAL INDENTURE (this “First Supplemental Indenture”) dated as of December 10, 2014 between ANI PHARMACEUTICALS, INC., a Delaware corporation, as issuer (the “Company”) and THE BANK OF NEW YORK MELLON, a New York banking corporation, as trustee (the “Trustee”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 18th, 2008 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of December 15, 2008, is by and between BIOSANTE PHARMACEUTICALS INC. (the “Company”) and KINGSBRIDGE CAPITAL LIMITED (the “Investor”).
EXHIBIT 10.30 INCENTIVE STOCK OPTION AGREEMENT THIS AGREEMENT is entered into and effective as of this ____ day of ____, ____ (the "Date of Grant"), by and between BioSante Pharmaceuticals, Inc., a Delaware corporation (the "Company"), and...Incentive Stock Option Agreement • March 26th, 2004 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Illinois
FORM OF INDEMNIFICATION AGREEMENTIndemnification Agreement • February 29th, 2024 • Ani Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT, made and executed this __ day of ________, 202_, by and between ANI Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and ____________, an individual resident of the State of ________ (the “Indemnitee”).
DEALER]1Call Option Transaction • August 13th, 2024 • Ani Pharmaceuticals Inc • Pharmaceutical preparations
The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between [DEALER] (“Dealer”) and ANI Pharmaceuticals, Inc. (“Counterparty”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. Each party further agrees that this Confirmation together with the Agreement evidence a complete binding agreement between Counterparty and Dealer as to the subject matter and terms of the Transaction to which this Confirmation relates, and shall supersede all prior or contemporaneous written or oral communications with respect thereto.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 21st, 2010 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of June 20, 2010, between BioSante Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
1,898,735 Shares of Common Stock ANI PHARMACEUTICALS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • May 12th, 2023 • Ani Pharmaceuticals Inc • Pharmaceutical preparations • New York
ANI Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 1,898,735 shares (the “Firm Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”). The Company also proposes to issue and sell to the several Underwriters up to an additional 284,810 shares (the “Additional Shares”) of Common Stock at the option of the Underwriters as provided in Section 2(c) below. The Firm Shares and any Additional Shares purchased by the Underwriters are referred to herein as the “Shares.” Guggenheim Securities, LLC (“Guggenheim Securities”) is acting as representative (the “Representative”) of the several Underwriters in connection with the offering and sale of the Shares contemplated herein (the “Offering”).
